Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.73 |
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL3485478 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL21925058 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL571284 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27709284 | 0.98 | SLC7A5 (0.71) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL22207546 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL2723438 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27074660 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL22654492 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL5066575 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27765246 | 0.95 | SLC7A5 (0.75) | SLC7A5GSRITGB3ITGA2BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298227-A1 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers | President and Fellows of Harvard College and Yeda Research | 2010-11-25 | — | — | US | claimed |
| WO-2002086153-A1 | DETERMINING RESISTANCE TO A $G(b)-LACTAM-CONTAINING ANTIBIOTIC BY COMPARING THE RATIO OF TWO $G(b)-LACTAMASE GENES | DIATECH PTY LTD (AU) | 2002-10-31 | — | — | WO | claimed |
| CN-109750019-A | It is a kind of to improve monocot crops to the method and application of gibberellin inhibitor sensitiveness | 中国农业大学 | 2019-05-14 | — | — | CN | disclosed |
| US-7741019-B2 | Detection of ovarian cancer | MOUNT SINAI HOSPITAL (CA) | 2010-06-22 | — | — | US | disclosed |
| CN-1938042-B | Use of aromatic cationic peptides for the manufacture of a medicament for the reduction of oxidative damage | CORNELL RES FOUNDATION INC | 2010-06-02 | — | — | CN | disclosed |
| US-20090280179-A1 | Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material | DOT GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
| CN-100536909-C | method for preventing mitochondrial permeability transition | CORNELL RES FOUNDATION INC CLI (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-101378789-A | Reabsorabable calcium phosphate based biopolymer-cross-linked bone replacement material | DOT GMBH (DE) | 2009-03-04 | — | — | CN | disclosed |
| CN-101214380-A | Method and carrier complexes for delivering molecules to cells | CORNELL RES FOUNDATION INC (US) | 2008-07-09 | — | — | CN | disclosed |
| US-7204997-B2 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2007-04-17 | — | — | US | disclosed |
| US-20060223059-A1 | Methods for detecting endocrine cancer | MOUNT SINAI HOSPITAL (CA) | 2006-10-05 | — | — | US | disclosed |
| EP-1330652-A2 | METHOD FOR DETECTING OVARIAN CANCER BASED ON HUMAN KALLIKREIN 6 (HK6) | MOUNT SINAI HOSPITAL (CA) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003034068-A1 | LOCALIZATION OF DISORDERS ASSOCIATED WITH KALLIKREINS | MOUNT SINAI HOSPITAL (CA) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033731-A2 | METHODS FOR DETECTING OVARIAN CANCER | MOUNT SINAI HOSPITAL (CA) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002097438-A1 | METHOD OF DETECTING AND MONITORING PROSTATE AND OVARIAN CANCERS | MOUNT SINAI HOSPITAL (CA) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002086153-A1 | DETERMINING RESISTANCE TO A $G(b)-LACTAM-CONTAINING ANTIBIOTIC BY COMPARING THE RATIO OF TWO $G(b)-LACTAMASE GENES | DIATECH PTY LTD (AU) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002037112-A2 | DETECTION OF OVARIAN CANCER | MOUNT SINAI HOSPITAL (CA) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002035232-A2 | METHOD FOR DETECTING OVARIAN CANCER BASED ON HUMAN KALLIKREIN 6 (HK6) | MOUNT SINAI HOSPITAL (CA) | 2002-05-02 | — | — | WO | disclosed |
| US-5141870-A | Transforming plants with mutant fragment confers herbicide resistance | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| US-4153687-A | Derivatives, having an inhibitory action against protease and an antiphlogistic action, of the trypsin-kallikrein inhibitor obtained from cattle organs (BPTI), their preparation and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280179-A1 | Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material | BMP2, BMP4, PLOD3 | PTGS1 2624/4885PTGS2 3176/4885SLC7A5 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.